Longevity research has shifted from theoretical gerontology — asking why organisms age — to pharmacological intervention: attempting to slow, halt, or reverse the aging process itself. The field has attracted more than $5 billion in private investment since 2020, with Altos Labs (backed by $3 billion), Calico (Alphabet), Unity Biotechnology, and dozens of startups pursuing cellular reprogramming, senescent cell elimination, and metabolic optimization. Multiple compounds that reliably extend lifespan in animal models are now in human clinical testing. The question is no longer whether aging can be modified in a lab dish. The question is whether it can be modified in a living human being — and whether the modifications produce years worth living.
The Biology of Aging: Nine Hallmarks
The modern framework for understanding aging was established by Dr. Carlos Lopez-Otin (University of Oviedo) and colleagues in a landmark 2013 Cell paper that identified nine hallmarks of aging: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication. Each hallmark is both a cause and a consequence of aging, and they interact in complex feedback loops. Nearly every current longevity intervention targets one or more of these hallmarks.
Dr. Nir Barzilai, director of the Institute for Aging Research at Albert Einstein College of Medicine and one of the most respected figures in the field, has emphasized that aging is the single largest risk factor for every major chronic disease. "Heart disease, cancer, diabetes, Alzheimer's — these are not independent conditions. They are symptoms of aging. If you slow aging, you delay all of them simultaneously." This insight — that targeting aging itself may be more efficient than targeting individual diseases — is the conceptual foundation of the entire field.
Rapamycin: The Most Proven Compound
Rapamycin, originally developed as an immunosuppressant for organ transplant recipients, is the most consistently validated lifespan-extending compound in animal models. It extends median lifespan by 10–25% in mice through inhibition of mTOR (mechanistic target of rapamycin), a nutrient-sensing pathway that, when active, promotes cell growth and suppresses autophagy — the cellular recycling process that clears damaged proteins and organelles. When mTOR is suppressed by rapamycin, autophagy increases, cellular maintenance improves, and age-related deterioration slows.
The human translation is underway. A 2024 Phase 2 trial at the University of Washington (n=150, ages 55–75, led by Dr. Matt Kaeberlein, formerly of the University of Washington and now CEO of Optispan) is testing low-dose rapamycin (1 mg, 3 times weekly) for immune function improvement in healthy older adults. A 2014 Science Translational Medicine study (n=264, led by Dr. Joan Mannick, now at Tornado Therapeutics) demonstrated that a rapamycin analog (RAD001/everolimus) improved influenza vaccine response by 20% in elderly adults — the first evidence that mTOR inhibition could rejuvenate immune function in humans.
The Dog Aging Project, the largest-ever aging intervention study in a non-laboratory species, is tracking 32,000 companion dogs across the United States and testing low-dose rapamycin in a subset. Dr. Daniel Promislow (University of Washington) leads the project. Preliminary cardiac data suggest improved diastolic function in treated dogs, though the primary lifespan endpoints are years from readout. If rapamycin extends lifespan in dogs — which share our environment, diet, and many age-related diseases — the case for human translation becomes substantially stronger.
Senolytics: Clearing Zombie Cells
Cellular senescence is a process in which damaged or stressed cells permanently stop dividing but do not die. Instead, they accumulate in tissues and secrete a cocktail of inflammatory molecules, growth factors, and matrix-degrading enzymes collectively called the senescence-associated secretory phenotype (SASP). These "zombie cells" — alive but non-functional and actively harmful — contribute to tissue dysfunction, chronic inflammation, and age-related disease.
Dr. James Kirkland, professor of medicine at Mayo Clinic and a pioneer of senolytic therapy, identified the combination of dasatinib (a cancer drug) and quercetin (a plant flavonoid) as the first compound pair capable of selectively eliminating senescent cells while sparing healthy cells. In mouse models, this combination extends healthspan by 36% and reduces age-related pathology across multiple organ systems.
A 2024 Phase 2 trial (n=48) is testing senolytics for idiopathic pulmonary fibrosis, with preliminary results showing improved 6-minute walk distance by 21.5 meters — a clinically meaningful improvement in a disease with limited treatment options. Larger trials are needed, and the long-term safety profile of periodic senolytic treatment in humans remains to be established. The idea of taking a drug intermittently (a few days per month) to clear accumulated damage rather than continuously suppressing a pathway is novel and, if validated, could represent a fundamentally new pharmacological paradigm.
NAD+ Precursors: The Billion-Dollar Bet Without Proof
Nicotinamide adenine dinucleotide (NAD+) is a coenzyme essential to cellular energy metabolism. NAD+ levels decline with age, and restoring them has become one of the most commercially successful longevity strategies — an estimated 3 million Americans currently supplement with NAD+ precursors (NMN or NR), generating over $1 billion in annual supplement sales.
The basic science is strong. Dr. David Sinclair, professor of genetics at Harvard Medical School, has demonstrated that NAD+ supplementation activates sirtuins — a family of proteins involved in DNA repair, mitochondrial function, and metabolic regulation. In mouse models, NMN supplementation restores NAD+ levels and improves vascular function, exercise capacity, and insulin sensitivity in aged animals.
The human evidence is less convincing. Human studies confirm that NMN supplementation at 250 mg daily increases blood NAD+ levels by 38–45% within two weeks. But elevating a biomarker is not the same as improving health. A 2023 review in Aging Cell (k=18 trials) concluded that no human trial has demonstrated improved healthspan or lifespan outcomes from NAD+ precursor supplementation. Individual studies show modest improvements in specific metrics — a Japanese trial found improved muscle function in older men; a Chinese trial found improved cardiovascular fitness — but the effects are small, inconsistent across studies, and far from the dramatic rejuvenation seen in mice. The gap between animal promise and human proof remains the defining feature of NAD+ supplementation.
Metformin: The TAME Trial
Metformin, the most widely prescribed diabetes medication in the world (150 million prescriptions annually), may be the first drug tested specifically to slow aging in a large human trial. Dr. Barzilai's TAME (Targeting Aging with Metformin) trial — the first FDA-approved trial targeting aging itself as an indication rather than a specific disease — will enroll 3,000 participants ages 65–79 and track the onset of age-related diseases over 5–7 years.
The observational evidence is intriguing. A 2014 Diabetes, Obesity and Metabolism study (n=180,000) found that diabetic patients on metformin lived 15% longer than matched non-diabetic controls — a striking finding because diabetics normally have shorter life expectancy. Metformin activates AMPK (an energy-sensing pathway), reduces mTOR signaling, lowers chronic inflammation, and improves insulin sensitivity — hitting multiple hallmarks of aging simultaneously. At approximately $4 per month, it would be the most affordable longevity intervention ever validated, if the TAME results are positive.
The concern: a 2019 Aging Cell study (n=14) found that metformin blunted the mitochondrial adaptations to exercise in older adults — meaning it may interfere with one of the best-established longevity interventions (exercise) while pursuing an unproven one. Whether this interaction is clinically meaningful at population scale is one of the questions TAME will help answer.
What Actually Works Right Now
The current evidence-based longevity protocol is, frankly, unremarkable. Regular exercise — 150 minutes of moderate or 75 minutes of vigorous activity weekly — reduces all-cause mortality by 31% (2022 British Journal of Sports Medicine meta-analysis, n=196,000). Adding two sessions of resistance training per week reduces mortality risk by an additional 10–17%. Sleep 7–9 hours consistently. Eat a diet rich in whole foods, particularly vegetables, legumes, nuts, and fatty fish. Maintain social connections — loneliness carries a mortality risk equivalent to smoking 15 cigarettes daily, per a 2023 WHO advisory led by U.S. Surgeon General Dr. Vivek Murthy. Manage blood pressure below 130/80 mmHg and fasting glucose below 100 mg/dL.
These interventions lack the glamour of rapamycin or senolytics, but they have something the pharmaceutical candidates do not: decades of human evidence demonstrating that they work. Dr. Peter Attia, author of Outlive: The Science and Art of Longevity, frames this as "Medicine 3.0" — a shift from treating disease after diagnosis to proactively optimizing the inputs that delay disease onset. His clinical protocol emphasizes zone 2 cardiovascular training (sustained moderate effort that builds mitochondrial density), grip strength as a longevity biomarker (the landmark 2015 Lancet PURE study of 140,000 participants found that each 5 kg decrease in grip strength correlated with a 17% increase in cardiovascular mortality), and maintaining lean muscle mass through progressive resistance training well into the seventh and eighth decades of life.
The most honest assessment of longevity science in 2026 is that the pharmacological future is genuinely exciting, the animal data are compelling, the human trials are underway — and the best thing you can do today is still exercise, sleep, eat well, and stay connected. The compounds may eventually prove to be powerful additions to that foundation. They are not yet replacements for it.